MBI-226. Micrologix/Fujisawa.
Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated.
D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D016470:Bacteremia / Q000517:prevention & control*; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D012869:Skin Absorption; D013329:Structure-Activity Relationship
D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; C478918:omiganan pentahydrochloride